Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 68.29

-2.0%

Nov 4 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (1760)	2/11/2008 1:31:59 PM
From: Jibacoa	Read Replies (2) of 3722

PCYC was up 20.4% at its intraday H & still is up 12.27% at present. Volume of 130,134 is getting close to its ADV. bigcharts.marketwatch.com It announced today the publication of data on its HDAC. The study, entitled "A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas," appears in the February 7 issue of Leukemia. Results from the in-vitro study demonstrate that PCYC's HDAC inhibitor,PCI-34051, inhibits HDAC8 with 200-1000 fold selectivity over other HDAC enzymes, & the selective inhibition of HDAC8 inhibits cell growth and induces apoptosis in cell lines derived from T-cell lymphoma and leukemia, but not in other hematopoietic or solid tumor lines. PCYC's lead pan-HDAC inhibitor, PCI-24781, is currently in a P1 in patients with solid and hematologic tumors. The stock still isn't off from the near term DT coming from its Dec 21 H at $2.38. It needs to close the DGs on Dec24 & Dec26 The "analysts" have a target around $3.50 The stock trades around 0.7xBV & the insiders reportedly hold > 15% with a fair institutional following. The short ratio is around 12x its ADV bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next